Improved survival after acute myocardial infarction in patients with advanced Killip class

W L Miller1, R S Wright, J P Grill

  • 1Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA.

Clinical Cardiology
|November 4, 2000
PubMed

Insights

The Killip classification effectively predicts outcomes in acute myocardial infarction (MI) patients, even with modern reperfusion therapies. Advanced Killip classes correlate with higher mortality and complications, highlighting the need for optimized medical therapy alongside interventions.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Medical Prognostics

Background:

  • The Killip classification system's utility in stratifying acute myocardial infarction (MI) outcomes requires reevaluation with current reperfusion treatments.
  • Assessing the Killip classification's role in predicting short-term and long-term prognosis is crucial for treatment strategy.
  • Modern primary reperfusion therapies necessitate a contemporary analysis of the Killip classification's applicability.

Purpose of the Study:

  • To test if the Killip classification, assessed upon admission for acute MI, accurately predicts in-hospital mortality and long-term survival.
  • To evaluate the Killip classification as an early prognostic tool in acute myocardial infarction (MI) patients.
  • To determine the predictive value of the Killip classification in the era of primary reperfusion therapy.

Main Methods:

  • Analysis of 909 consecutive Olmsted County patients admitted with acute MI between 1988 and 1998.
  • Killip classification assessed on admission served as the primary variable.
  • Endpoints included in-hospital death, major in-hospital complications, and post-hospital death.

Main Results:

  • In-hospital mortality significantly increased with advanced Killip class (7% Class I, 17.6% Classes II/III, 36% Class IV).
  • Higher Killip classes showed a significant correlation with increased in-hospital mortality and complications (p < 0.01).
  • Killip classification strongly influenced 24-hour treatment strategies, with Class IV patients more likely to receive primary angioplasty.

Conclusions:

  • The Killip classification remains a robust independent predictor of in-hospital mortality, complications, and long-term survival.
  • While primary angioplasty has improved outcomes for Killip IV patients, adjunctive medical therapy is underutilized.
  • The Killip classification continues to be a valuable tool for risk stratification in acute myocardial infarction (MI).
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...